Comments Leave a Comment

    1-15 of 231 1 2 3 4 ... 14 15 16 »
    1. Mentioned In 231 Articles

    2. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      ...e 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experie...
      Read Full Article
      Mentions: Treatment MYCN
    3. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      ...year estimated survival rates were lower for patients diagnosed with stage 4 disease, unfavorable DNA ploidy, MYCN gene amplification or classified as high-risk. Most neuroblastoma patients are registered on a risk-based...
      Read Full Article
      Mentions: Treatment COG MYCN
    4. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.

      ...PRC2 in HR-NB cells. A significant concurrence existed between exons with verified variants and genes showing MYCN-dependent expression in HR-NB. From these biomarker candidates, we identified two novel prognostic gene-s...
      Read Full Article
      Mentions: MYCN
    5. 1-15 of 231 1 2 3 4 ... 14 15 16 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about MYCN

    1. Children with a MYCN-amplification event, which occurs in about 25 percent of cases, have the poorest prognosis.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    2. Once a tumor has disrupted let-7 genetically, it doesn't need to amplify MYCN because it doesn't need to sponge let-7.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    3. We showed that maintenance of high MYCN protein levels is a key issue for this MYCN driven cancer. Neuroblastoma cells often have over 100 copies of the MYCN gene - so they produce an enormous amount of MYCN protein.
      In A way to target the Achilles heel of neuroblastoma